Transdermal delivery rate control using amorphous pharmaceutical compositions

Transdermal delivery rate control using amorphous pharmaceutical compositions

A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: WILKINS, NINA, FRANCES, REED, BARRY, LEONARD, KLOSE, KATHRYN, TRACI-JANE, MORGAN, TIMOTHY, MATTHIAS, FINNIN, BARRIE, CHARLES
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator WILKINS, NINA, FRANCES
REED, BARRY, LEONARD
KLOSE, KATHRYN, TRACI-JANE
MORGAN, TIMOTHY, MATTHIAS
FINNIN, BARRIE, CHARLES
description A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP2266533A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP2266533A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP2266533A23</originalsourceid><addsrcrecordid>eNqNyzEKAjEQQNE0FqLeYS5gk-D2Iis2gsX2y5Ad3UCSCTOJ4O1N4QGsfvP-1twnwawLScIIC8XwJvmAYCXwnKtwhKYhvwATS1m5KZQVu_bUavB98pwKa6iBs-7N5olR6fDrzsB1nC63IxWeSUu_MtV5fFg7DCfnztb9Qb4TlTcw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Transdermal delivery rate control using amorphous pharmaceutical compositions</title><source>esp@cenet</source><creator>WILKINS, NINA, FRANCES ; REED, BARRY, LEONARD ; KLOSE, KATHRYN, TRACI-JANE ; MORGAN, TIMOTHY, MATTHIAS ; FINNIN, BARRIE, CHARLES</creator><creatorcontrib>WILKINS, NINA, FRANCES ; REED, BARRY, LEONARD ; KLOSE, KATHRYN, TRACI-JANE ; MORGAN, TIMOTHY, MATTHIAS ; FINNIN, BARRIE, CHARLES</creatorcontrib><description>A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20101229&amp;DB=EPODOC&amp;CC=EP&amp;NR=2266533A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20101229&amp;DB=EPODOC&amp;CC=EP&amp;NR=2266533A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WILKINS, NINA, FRANCES</creatorcontrib><creatorcontrib>REED, BARRY, LEONARD</creatorcontrib><creatorcontrib>KLOSE, KATHRYN, TRACI-JANE</creatorcontrib><creatorcontrib>MORGAN, TIMOTHY, MATTHIAS</creatorcontrib><creatorcontrib>FINNIN, BARRIE, CHARLES</creatorcontrib><title>Transdermal delivery rate control using amorphous pharmaceutical compositions</title><description>A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyzEKAjEQQNE0FqLeYS5gk-D2Iis2gsX2y5Ad3UCSCTOJ4O1N4QGsfvP-1twnwawLScIIC8XwJvmAYCXwnKtwhKYhvwATS1m5KZQVu_bUavB98pwKa6iBs-7N5olR6fDrzsB1nC63IxWeSUu_MtV5fFg7DCfnztb9Qb4TlTcw</recordid><startdate>20101229</startdate><enddate>20101229</enddate><creator>WILKINS, NINA, FRANCES</creator><creator>REED, BARRY, LEONARD</creator><creator>KLOSE, KATHRYN, TRACI-JANE</creator><creator>MORGAN, TIMOTHY, MATTHIAS</creator><creator>FINNIN, BARRIE, CHARLES</creator><scope>EVB</scope></search><sort><creationdate>20101229</creationdate><title>Transdermal delivery rate control using amorphous pharmaceutical compositions</title><author>WILKINS, NINA, FRANCES ; REED, BARRY, LEONARD ; KLOSE, KATHRYN, TRACI-JANE ; MORGAN, TIMOTHY, MATTHIAS ; FINNIN, BARRIE, CHARLES</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP2266533A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2010</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>WILKINS, NINA, FRANCES</creatorcontrib><creatorcontrib>REED, BARRY, LEONARD</creatorcontrib><creatorcontrib>KLOSE, KATHRYN, TRACI-JANE</creatorcontrib><creatorcontrib>MORGAN, TIMOTHY, MATTHIAS</creatorcontrib><creatorcontrib>FINNIN, BARRIE, CHARLES</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WILKINS, NINA, FRANCES</au><au>REED, BARRY, LEONARD</au><au>KLOSE, KATHRYN, TRACI-JANE</au><au>MORGAN, TIMOTHY, MATTHIAS</au><au>FINNIN, BARRIE, CHARLES</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Transdermal delivery rate control using amorphous pharmaceutical compositions</title><date>2010-12-29</date><risdate>2010</risdate><abstract>A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre ; ger
recordid cdi_epo_espacenet_EP2266533A2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Transdermal delivery rate control using amorphous pharmaceutical compositions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A04%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WILKINS,%20NINA,%20FRANCES&rft.date=2010-12-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP2266533A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true